Evénements Archive - Page 4 of 5 - Ose Immunotherapeutics - Société de biotechnologie intégrée qui développe des immunothérapies innovantes
Evénements Archive - Page 4 of 5 - Ose Immunotherapeutics - Société de biotechnologie intégrée qui développe des immunothérapies innovantes
  • Our Company
    • Presentation
    • Management Team
    • Board of directors
    • Scientific Advisory Board
    • Contact
  • Products
    • Tedopi®
    • OSE-279
    • Lusvertikimab (OSE-127)
    • Pegrizeprument (FR104)
    • BI 770371
    • ABBV-230
    • CLEC-1
  • Research & Development
    • Scientific publications
  • Investors
    • Press Releases
    • Regulated information
    • Financial documents
    • General Shareholders’ meetings
  • Partnerships
    • Pharma partnerships
    • Clinical partnerships
    • Academic and public Partnerships
  • News
    • Agenda
    • Press Releases
  • Contact
en
  • fr

P
r
o
j
e
c
t
s
A
r
c
h
i
v
e
s

June 2022

Conference call for analysts to comment the updated data presented at the 2022 ASCO meeting
May 2022

2022 ASCO Annual Meeting
April 2022

American Association for Cancer Research Annual (AACR) Meeting 2022
February 2022

‘European Midcap’ Event
February 2022

Investor Access Event Paris
February 2022

‘Midcap Event’ Paris
February 2022

Investor Access Event Paris
February 2022

‘Smallcap Event’ Paris
February 2022

Maxim Group 2022 Virtual Growth Conference
February 2022

European ‘Midcap Event’
  • Précédent
  • 1
  • 2
  • 3
  • 4
  • 5
  • Suivant

Head Office

22, boulevard Benoni Goulin
44200 Nantes – France

Tel : +33 (0)2 28 29 10 10

Email : contact@ose-immuno.com

Paris Office

10, place de Catalogne
75014 Paris – France

Tel : +33 (0)1 43 29 78 57

Fax : +33 (0)1 42 03 04 16

Our Company
Products
Investors
Agenda
Research & Development
Partnerships
Press Releases
Follow us
©2021 ose-immuno
Financial documents
Legal information and Personal data protection policy
Site internet créé par Adveris